Exploring factors related to clinically advanced fibrosis in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis.

Postgraduate medicine Pub Date : 2024-01-01 Epub Date: 2023-11-30 DOI:10.1080/00325481.2023.2288560
Anthony Yu, Alexandra Ritenour, Jennifer Vincent, Chanhyun Park, Karen Rascati, Paul Godley
{"title":"Exploring factors related to clinically advanced fibrosis in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis.","authors":"Anthony Yu, Alexandra Ritenour, Jennifer Vincent, Chanhyun Park, Karen Rascati, Paul Godley","doi":"10.1080/00325481.2023.2288560","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To describe the clinical profile of nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH) patients in a Texas integrated delivery network (IDN) and elucidate the local relationship between patient factors and the risk of advanced fibrosis.</p><p><strong>Methods: </strong>This observational, retrospective, cross-sectional study utilized existing data from the electronic health record at a large Texas IDN. Data was collected during the study period from 1 January 2019, to 1 March 2023. Patient characteristics, comorbidities, labs, and medication orders were collected from the most recent encounter in which a Fibrosis-4 (FIB-4) score could be calculated. Chi square tests and analysis of variance (ANOVA) tests were conducted to evaluate differences among the three fibrosis risk categories. Ordinal logistic regression was utilized to assess associations between select variables and a higher risk of advanced fibrosis.</p><p><strong>Results: </strong>A total of 56,253 patients were included in the study. 34,839 (61.9%) were Low-Risk 15,578 (27.7%) were Intermediate-Risk, and 5,836 (10.4%) were High-Risk of advanced fibrosis. Results showed that up to 70.4% of patients within a risk group were obese. Only 49.5% of patients in the High-Risk group had at least one gastroenterologist or hepatologist visit. Males, Medicare patients, former smokers, and those with hypertension, type 2 diabetes, and chronic kidney disease were associated with a higher risk of advanced fibrosis.</p><p><strong>Conclusion: </strong>This study highlights the need for early screening and proactive management of metabolic risk factors for patients with NAFLD/NASH. The findings indicate a notable prevalence of obesity in the study population, a need for specialist referral for those at High-Risk of advanced fibrosis, and the importance of routine labs to evaluate metabolic factors. Primary care providers may be ideal providers to target these interventions and address this care need.</p>","PeriodicalId":94176,"journal":{"name":"Postgraduate medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Postgraduate medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/00325481.2023.2288560","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/30 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: To describe the clinical profile of nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH) patients in a Texas integrated delivery network (IDN) and elucidate the local relationship between patient factors and the risk of advanced fibrosis.

Methods: This observational, retrospective, cross-sectional study utilized existing data from the electronic health record at a large Texas IDN. Data was collected during the study period from 1 January 2019, to 1 March 2023. Patient characteristics, comorbidities, labs, and medication orders were collected from the most recent encounter in which a Fibrosis-4 (FIB-4) score could be calculated. Chi square tests and analysis of variance (ANOVA) tests were conducted to evaluate differences among the three fibrosis risk categories. Ordinal logistic regression was utilized to assess associations between select variables and a higher risk of advanced fibrosis.

Results: A total of 56,253 patients were included in the study. 34,839 (61.9%) were Low-Risk 15,578 (27.7%) were Intermediate-Risk, and 5,836 (10.4%) were High-Risk of advanced fibrosis. Results showed that up to 70.4% of patients within a risk group were obese. Only 49.5% of patients in the High-Risk group had at least one gastroenterologist or hepatologist visit. Males, Medicare patients, former smokers, and those with hypertension, type 2 diabetes, and chronic kidney disease were associated with a higher risk of advanced fibrosis.

Conclusion: This study highlights the need for early screening and proactive management of metabolic risk factors for patients with NAFLD/NASH. The findings indicate a notable prevalence of obesity in the study population, a need for specialist referral for those at High-Risk of advanced fibrosis, and the importance of routine labs to evaluate metabolic factors. Primary care providers may be ideal providers to target these interventions and address this care need.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
探讨非酒精性脂肪性肝病或非酒精性脂肪性肝炎患者临床晚期纤维化相关因素
目的:描述德克萨斯州综合递送网络(IDN)中非酒精性脂肪性肝病(NAFLD)或非酒精性脂肪性肝炎(NASH)患者的临床概况,并阐明患者因素与晚期纤维化风险之间的局部关系。方法:这项观察性、回顾性、横断面研究利用了来自德克萨斯州大型IDN电子健康记录的现有数据。数据收集于2019年1月1日至2023年3月1日的研究期间。收集患者特征、合并症、实验室和用药单,计算纤维化-4 (FIB-4)评分。采用卡方检验和方差分析(ANOVA)检验来评价三种纤维化风险类别之间的差异。使用有序逻辑回归来评估所选变量与晚期纤维化高风险之间的关联。结果:共纳入56253例患者。34,839例(61.9%)为低危,15,578例(27.7%)为中危,5,836例(10.4%)为高危晚期纤维化。结果显示,风险组中高达70.4%的患者肥胖。高风险组中只有49.5%的患者至少就诊过一次胃肠病学或肝病学专家。男性、医疗保险患者、前吸烟者、高血压、2型糖尿病和慢性肾脏疾病患者发生晚期纤维化的风险较高。结论:本研究强调了NAFLD/NASH患者早期筛查和主动管理代谢危险因素的必要性。研究结果表明,肥胖在研究人群中显著流行,晚期纤维化高危人群需要专科转诊,以及常规实验室评估代谢因素的重要性。初级保健提供者可能是针对这些干预措施和解决这一护理需求的理想提供者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
The triglyceride-glucose index as an indicator of latent atherogenicity of the plasma lipid profile in healthy men with normolipidaemia. Pentoxifylline improves anemia through its novel effect on hypoxia-inducible factor-2 alpha in hemodialysis patients: a randomized, double-blind, placebo-controlled clinical trial. The masters athlete and use of antihypertensive medications. Evaluating cardiac electrophysiological markers for predicting arrhythmic risk in hypothyroid patients. SGLT2 inhibitors across the spectrum of chronic kidney disease: a narrative review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1